Caricamento...
Generation, characterization, and maintenance of trastuzumab-resistant HER2+ breast cancer cell lines
Trastuzumab became the therapy of choice for patients with HER2-positive breast cancer in 1998, and it has provided clinical benefit ever since. However, a significant percentage of patients show primary resistance to trastuzumab at diagnosis, and most patients with metastatic disease that initially...
Salvato in:
| Pubblicato in: | Am J Cancer Res |
|---|---|
| Autori principali: | , , , , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
e-Century Publishing Corporation
2016
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5126281/ https://ncbi.nlm.nih.gov/pubmed/27904779 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|